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Diabetic retinopathy is a serious long-term complication of diabetes mellitus. There is considerable interest in using mouse
models, which can be genetically modified, to understand how retinopathy develops and can be inhibited. Not all retinal
lesions that develop in diabetic patients have been reproduced in diabetic mice; conversely, not all abnormalities found
in diabetic mice have been studied or identified in diabetic patients. Thus, it is important to recognize which structural
and functional abnormalities that develop in diabetic mice have been validated against the lesions that characteristically
develop  in  diabetic  patients.  Those  lesions  that  have  been  observed  to  develop  in  the  mouse  models  to  date  are
predominantly characteristic of the early stages of retinopathy. Identification of new therapeutic ways to inhibit these early
lesions is expected to help inhibit progression to more advanced and clinically important stages of retinopathy.
Studies  in  diabetic  animals  have  provided  valuable
insight into the pathogenesis of diabetic retinopathy (DR). For
example, studies of diabetic dogs demonstrated that improved
glycemic  control  could  inhibit  the  development  of  the
retinopathy  more  than  16  years  before  a  comparable
demonstration  in  diabetic  patients  [1].  The  possibility  of
genetic manipulation, and the availability of reagents and
antibodies for molecular studies, has led to great interest in
smaller  species  such  as  the  mouse  for  studies  of  DR.  In
addition,  the  development  of  noninvasive,  translational
imaging methods that can be applied to both humans and
animals has opened new opportunities for investigating the
pathophysiology of DR. Several laboratory species have been
compared with regard to which retinal lesions develop in
diabetes,  with  the  general  conclusion  that  more  types  of
lesions  develop  in  larger,  longer-lived  models  (primates,
dogs) than in smaller, shorter-lived models (rats, mice) [2].
At present, a range of anatomic and functional retinal
lesions linked with DR have been identified by a variety of
methods. The identification of the lesions that are most critical
to  this  retinopathy,  as  well  as  the  methods  that  best
demonstrate these abnormalities, has been controversial. In
the present text, “robust” lesions are defined as those that
occur  in  both  human  and  mouse  models,  and  have  been
identified  by  different  laboratories,  independent  of  the
methods used. This category does not rule out the possibility
that other retinal lesions represent real and important damage
inflicted on the retina by diabetes, but indicates only that
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important  inconsistencies  and/or  questions  remain  in  the
literature. To aid future efforts at translational studies, in this
review, we will emphasize existing anatomic and physiologic
lesions that fit this classification.
1. DIABETIC RETINOPATHY IN HUMANS
DR is a common complication of diabetes, and one of the
leading causes of visual loss in working age populations in
developed countries. It has been found to affect the majority
of patients who have had diabetes for 1–2 decades, although
not  all  patients  develop  a  comparable  severity  of  retinal
disease. The major risk factors of DR are the degree and
duration of hyperglycemia. The retinal lesions that develop in
type 1 diabetes are not different from those that develop in
type 2 diabetes, although the severity and/or incidence of the
lesions may differ. For example, the severity of retinal edema
and  neovascularization  differ  between  different  types  of
diabetes [3].
1A. Characteristic structural changes.
1A1.  Vascular  pathology—Clinically  detectable
characteristics of DR have focused on damage to the retinal
vasculature. Based on vascular changes, DR is subdivided into
an early nonproliferative stage including progressive capillary
occlusion and degeneration (NPDR), and a more advanced,
proliferative  or  neovascular  stage  (PDR)  [4].  In  addition,
macular edema (i.e., retinal edema involving or threatening
the macula) can occur in both stages, can be diffuse or focal
in distribution, and can have a cystoid appearance or not.
Other vascular lesions of NPDR include the appearance
of microaneurysms, vascular nonperfusion, and degeneration
(Figure  1).  Capillary  degeneration  and  nonperfusion  are
tightly  associated,  but  it  remains  unclear  if  they  occur
independently of each other, or if one always causes the other.
Nonetheless, degenerate capillaries are very important lesions
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2121of  the  retinopathy;  they  lead  to  progressive  reductions  in
retinal perfusion, at least locally, as more and more capillaries
become occluded [5-7]. Appreciable increases in capillary
nonperfusion/degeneration  are  strongly  predictive  of  (and
likely  causally  related  to)  progression  to  the  advanced,
neovascular stages of retinopathy in patients. Selective loss of
pericytes is also common in DR, but perfusion can continue
in capillaries missing only some pericytes.
Microaneurysms, or dot hemorrhages, are focal dilations
of  individual  retinal  capillaries,  and  are  detectable
ophthalmoscopically in diabetic patients. Increasing numbers
of microaneurysms have a strong predictive value with respect
to the progression of retinopathy [8,9]. Signs of advanced
NPDR  include  venous  beading  and  loops,  intraretinal
microvascular  abnormalities,  and  large  areas  of  capillary
nonperfusion (as assessed using fluorescein angiography).
PDR is observed to develop in areas adjacent to extensive
vascular nonperfusion, which are presumably ischemic [10,
11].  This  advanced  stage  of  DR  is  characterized  by  the
appearance  of  new,  fragile,  and  fenestrated  retinal  blood
vessels that penetrate the inner limiting membrane and enter
the  vitreous  (i.e.,  preretinal  neovascularization).  These
delicate vessels hemorrhage easily. The resulting pooling of
blood  in  the  vitreous  will  reduce  in  the  amount  of  light
reaching the retina and potentially decrease vision. Perhaps
more importantly, fibrovascular scar tissue can form around
the neovascularization, producing retinal tears and tractional
detachment with subsequent blindness.
1A2. Neuroglial pathology—Diabetes can also damage
nonvascular cells of the retina. In autopsy samples, retinal
ganglion cells are lost, at least in part via apoptosis [12-19].
In  vivo  scanning  laser  polarimetry  or  optical  coherence
tomography (OCT) studies have also measured a thinning of
the nerve fiber layer in some diabetic patients [20-26]. It is not
yet known if ganglion cell loss in diabetic patients is severe
enough to contribute to impaired vision.
1A3.  Retinal  thickness—OCT  studies  have  also
identified retinal thickening and serous retinal detachment in
some diabetic patients [27-31]. However, some authors report
that  foveal  thickness  is  similar  among  diabetics  and
nondiabetics when data are controlled for age, race, and sex
[32].
1A4.  Permeability  and  edema—In  early  NPDR,
apparent focal increases in vascular permeability (as assessed
by focal accumulation of fluorescein near retinal vessels) are
clearly  associated  with  well  defined  microaneurysms
[33-35].  Diffuse  accumulation  also  occurs,  but  is  not
specifically associated with microaneurysms. These findings
do not rule out an alternative possibility that a functional
defect  leading  to  the  impaired  removal  of  fluorescein
contributes to the accumulation of the contrast agent as well
as to the edema [36,37]. Baseline fluorescein accumulation in
patients  with  DR  was  predictive  of  progression  to
photocoagulation  for  clinically  significant  macular  edema
[38].
1A5.  Glial  activation—Induction  of  glial  fibrillary
acidic protein (GFAP) is a marker of glial activation, and
upregulation of this protein occurs in Muller cells from the
retinas of diabetic patients [39]. Activation of macro- and
microglia occurs in the retinas of diabetic patients, but is of
unknown significance [39-43]. Vascular endothelial growth
factor,  which  is  strongly  implicated  in  retinal
neovascularization and permeability in diabetes, is produced
in retinal Muller cells [40].
1B. Characteristic functional defects: The above catalog
of structural lesions, while critical in the clinical management
of DR, provides little insight into the underlying mechanisms
or  pathophysiology  of  the  disease,  especially  during  its
emerging, clinically silent phase. The pathophysiology of DR
has also been extensively studied to better understand the
effects of diabetes on the retina. These investigations offer a
different perspective on retinal disease caused by diabetes.
1B1.  Perfusion  and  autoregulation—Much  research
has been directed at measuring diabetes-induced alterations in
retinal  perfusion,  although  there  has  been  substantial
disagreement in the literature regarding whether perfusion is
increased,  decreased,  or  unchanged  [44-48].  The  use  of
multiple different methods for monitoring plasma flow and
erythrocyte velocity and transit time has likely contributed to
the  disparate  findings.  Nevertheless,  steps  toward
Figure 1. Demonstration of clinical and
experimental  diabetes-induced
degenerate capillaries. Black arrows are
diabetes-induced degenerate capillaries
and pericyte ghosts are shown in white
arrow,  and  capillary  microaneurysm
(MA) in isolated retinal vessels. A: A
diabetic  patient  having  non
proliferavtive  diabetic  retinopathy
(NPDR). B: A C57Bl/6 mouse after nine
months of diabetes. Pericyte ghosts are
more difficult to detect in mice retinas
than in most other species.
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2122understanding  these  differences  come  with  evidence  that
perfusion changes are linked to levels of hyperglycemia and
increasing duration of diabetes, along with the severity of
retinopathy [47,49]. Retinal perfusion abnormalities are not
detectable in patients with tight glycemic control [50].
Measurements of retinal blood flow or perfusion have
commonly been made in the unchallenged retina, but since the
retinovascular system must constantly adapt to changes in
blood pressure and metabolic demand, it is rarely found at
steady-state.  Dynamic  studies  of  autoregulation,  unlike
perfusion measures [50], have robustly shown dysfunction of
the vascular system in DR [51-54] (Figure 2). Importantly,
retinal  autoregulatory  abnormalities  can  be  detected  in
patients with tight glycemic control [50]. Whether or not the
vascular  autoregulation  defects  or  retinal  perfusion
abnormalities in diabetes are of pathogenic importance is not
yet known.
1B2.  Retinal  function—Electrophysiological
assessments of the retinal function in DR have been made
using electroretinogram (ERG), multifocal ERG (mfERG),
and visual evoked potential. Diabetes-induced dysfunction
includes decreased b-wave amplitude, reduction of oscillatory
potential amplitude, and delay in oscillatory potential latency
[55-64]. Changes in ERG and mfERG have been used to
predict progression of the retinopathy [55-58,65]. ERG and
visual  evoked  potential  integrate  the  response  across  the
whole  retina  and  do  not  allow  the  detection  of  localized
abnormalities.  Seemingly  more  useful  is  mfERG,  which
allows for functional assessment of multiple small areas of the
central retina. Importantly, mfERG studies have been able to
analytically  predict  the  retinal  locations  of  new
nonproliferative DR development [65]. Another noninvasive
method for analytically evaluating intraretinal function with
good panretinal spatial resolution involves the measurement
of  retinal  ionic  regulation  using  manganese-enhanced
magnetic resonance imaging (MEMRI) [66]. A Food Drug
Administration (FDA)-approved manganese-based contrast
agent (Teslascan) is beginning to be used to assess clinical
applications of MEMRI in DR [67]
Diabetes  also  negatively  impacts  psychophysical
processes related to vision, such as contrast sensitivity, color
vision, and dark adaptation rates [68-71]. The reduction in
contrast sensitivity in patients with diabetes, despite normal
visual  acuity,  has  been  well  documented  [72,73],  and
significant losses of contrast sensitivity have been observed
in patients with insulin-dependent diabetes mellitus with no
evidence  of  retinopathy  when  compared  with  nondiabetic
controls [74-81]. Spatial frequencies in the mid to high range
are especially sensitive to diabetes [74,76,77,79,81]. These
defects  can  occur  before  overt  evidence  of  retinopathy  is
present [82]. Such deficits are not necessarily retina-specific,
and could reflect changes anywhere in the visual system (from
anterior  chamber  to  visual  cortex  and  higher  central
processing aspects in the brain). Diabetic patients take longer
to  dark  adapt  than  age-matched  controls  [68];  this
prolongation  is  likely  caused  by  alterations  in  the
photoreceptor/pigment epithelial complex.
2. MICE AS MODELS OF DIABETIC RETINOPATHY
A variety of different animal species (including primates,
dogs, cats, pigs, rats, and mice) have been used to investigate
the  pathogenesis  of  retinopathy.  The  advantages  and
disadvantages  of  those  species  have  been  summarized
elsewhere [2], and here we will focus only on mice, which
offer  considerable  promise  as  models  due  largely  to  the
availability of molecular tools to investigate the pathogenesis
of  the  disease.  To  date,  the  effects  of  diabetes  on  the
development of retinopathy in mice have been studied only in
a small number of strains, so the following summary likely
will need to be amended in the future.
Figure  2.  Diabetes  induces  defects  in
retinal vascular autoregulation in both
humans and mice. A: The retinal arterial
diameter response to stimulation with
flickering light in age- and sex-matched
controls  and  patients  with  type  1
diabetes  mellitus.  B:  Plot  of  superior
hemiretinal  ΔPO2  during  carbogen
breathing  indiabetic  mice  and  sex-
matched  nondiabetic  controls.  *
Significant difference (p<0.05). Figure
A has been modified from Investigative
Ophthalmology  and  Visual  Science
50:4029–32, 2009, and Figure B from
Diabetes  (Copyright  2010  American
Diabetes Association From Diabetes®,
Vol. 53, 2004; 173–178. Modified with
permission  from  The  American
Diabetes Association).
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2A1. Vascular pathology—Over a period of 6–9 months
of diabetes, several strains of mice (including the C57Bl/6J,
Ins2Akita,  db/db,  KK.Cg-Ay/J(KKAY),  and  Non-Obese
Diabetic strains) develop similar microvascular changes of the
retina  that  are  consistent  with  the  early  clinical  stages  of
NPDR (capillary degeneration, pericyte loss, thickening of the
capillary basement membrane) [83-88]. C57Bl/6J mice made
diabetic  with  streptozotocin  begin  to  show  capillary
degeneration  and  pericyte  loss  histologically  at  about  six
months  after  the  onset  diabetes  (Figure  1);  these  lesions
become  more  numerous  with  increasing  duration  of  the
diabetes  [88-90].  Males  of  the  Ins2Akita  strain  develop  a
spontaneous  type  1  diabetes  (females  are  less  severely
affected), with subsequent vascular histopathology [85] that
is  comparable  in  severity  and  progression  rate  to  that  in
streptozotocin-treated C57Bl/6 mice. Likewise, genetically
diabetic db/db mice (type 2 diabetes) develop strand-like and
degenerate capillaries, as well as an increase in the ratio of
endothelial cells to pericytes (interpreted as a loss of pericytes)
relative to nondiabetic controls [87,91]. Crossing db/db mice
with  apolipoprotein  E–deficient  mice  results  in  both
hyperglycemia and hyperlipidemia [86], and these crossed
mice exhibit accelerated degeneration of the retinal capillaries
and pericytes compared with littermate controls [86]. The KK
mouse strain exhibits pericyte ghosts, degenerate capillaries,
and occasional microaneurysms between 20 and 64 weeks of
age  [92].  Thus,  diabetic  mice  develop  a  similar  vascular
histopathology at prolonged progression rates to patients with
early DR.
Genetically  modified  diabetic  mice,  however,  can
develop these structural lesions at an accelerated rate. For
example, diabetic mice deficient in endothelial nitric oxide
synthase are reported to have an earlier onset and increased
number  of  acellular  capillaries,  sustained  gliosis,  and
increased capillary basement membrane thickness than that
reported for diabetic C57BL/6 mice [93]. In another example,
KKAY mice have changes in their retinal capillaries after only
three months of diabetes [84]. The changes reported were
relatively  nonspecific  (endothelial  hyperplasia,  basement
membrane  thickening,  and  some  edema  and  vacuolar
degeneration of capillary cells), whereas none of the more
characteristic  lesions  of  DR  (microaneurysms,  capillary
degeneration, pericyte loss, etc.) were discussed. Since the
lesions detected were present after only short durations of
diabetes, it is possible that they might be unrelated to diabetes.
Microaneurysms  comparable  to  the  saccular  capillary
lesions characteristic of diabetes in patients are not robustly
reported in C57Bl/6 or Ins2Akita mice [85,88,89,94]. Some KK
mice have been reported to show occasional microaneurysm-
like vascular abnormalities in old animals [92].
Thickening of the vascular basement membrane has been
detected in retinal capillaries in mice with chemically induced
[88,95]  and  spontaneous  diabetes  [96-98]  after  about  six
months diabetes. This change is not specific for the retina (as
it is also found in kidney, brain, and other sites [99,100]), or
even for diabetes [101].
A common criticism of the mouse model of DR is that it
apparently does not develop preretinal neovascularization or
other  advanced  lesions  (retinal  edema,  hemorrhages,
microaneurysms) of retinopathy [94,102]. The relatively short
duration of diabetes (most studies are <1 year) and mouse
lifespan, as well as the resulting modest extent of capillary
degeneration  that  develops  during  this  short  interval,  are
probable  reasons  that  neovascularization  has  not  been
observed in these models.
Nevertheless, some reports have claimed finding retinal
neovascularization.  Fifteen-month-old  db/db  mice  showed
increased density of retinal capillaries in the inner nuclear
layer,  which  was  interpreted  as  evidence  of  vessel
proliferation [87]. However, these vessels did not extend into
the vitreous body. J129sv/B16 mice diabetic for four months
have been reported to develop neovascularization; the claimed
new  vessels  were  demonstrated  by  injecting  a  contrast
medium  (black  ink)  into  the  vascular  lumen  [103].  The
“neovascularization”  was  poorly  demonstrated,  and  could
possibly be increased retinal vascular density within the retina
instead.
2A2. Neuroglial pathology—Neuronal cells of the retina
also are affected by diabetes, resulting in dysfunction and even
degeneration  of  some  neuronal  cells  in  humans  and  rats.
Findings in mice, however, are more controversial, and have
not necessarily been in agreement with findings in rats [88,
104-107].
The spontaneous development of diabetes resulted in loss
of cells in the ganglion cell layer in Ins2Akita mice [85,108].
After 5–6 months of hyperglycemia, there was a significant
reduction in the number of cell bodies in the retinal ganglion
cell layer, which was accompanied by a significant reduction
in the thickness of the inner plexiform layer in these animals.
By  crossing  Ins2Akita  with  mice  that  express  fluorescent
proteins under the regulation of the Thy1 promoter, Gastinger
et al. [109] demonstrated that diabetes caused 16% depletion
of ganglion cells from the peripheral retina, but not from the
central region. Dopaminergic and cholinergic amacrine cells
are also lost from the retina in diabetes [110].
The C57Bl/6J mouse strain has also been evaluated for
diabetes-induced  neurodegeneration  in  the  retina.  Some
investigators reported a 20% to 25% reduction in cells of the
ganglion cell layer of the retina at as early as 14 weeks of
diabetes [104,107,111]. Others did not detect any ganglion
cell loss at diabetes durations of up to one year [88,105,106,
112]. This difference between findings remains unexplained.
Fifteen-month-old  db/db  mice  were  reported  to  have
increased apoptosis of retinal ganglion cells and other cells of
the  neural  retina  [87].  After  one  month  of  diabetes,  the
numbers of apoptotic cells in the retinal ganglion cells and
inner nuclear layers were significantly greater in the diabetic
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death increased with duration of diabetes [84].
2A3. Retinal thickness—Studies of diabetic mice to date
have shown thinning of the retina [85,90], in contrast to the
retinal thickening seen in diabetic patients with retinal edema.
The relative thickness of retinal layers has been found to be
reduced in Ins2Akita mice after 22 weeks of hyperglycemia
[85], and in some (but not all) studies of C57Bl/6 mice made
diabetic  using  streptozotocin  [88,90,104,113].  As  diabetic
C57Bl/6 mice aged, MEMRI-derived measurements of retinal
thickness in vivo decreased in a linear fashion [66].
2A4. Permeability—A variety of techniques measuring
accumulation of material from plasma in the neural retina of
diabetic mice have been investigated to assess permeability
[85,89,114-118]. Such accumulation seems diffuse in nature,
and focal defects have not been reproducibly described in
diabetic  mice.  Importantly,  interpretations  of  techniques
involving such tracer accumulation have not been validated
in terms of the permeability surface area product (the gold
standard  metric  for  assessment  of  vascular  leakage).
Furthermore,  whether  or  not  the  detection  sensitivity  and
“lesion-type”  (i.e.,  paracellular  versus  intracellular  path
defects) sensitivity of these assays are similar has not been
established,  making  comparisons  between  laboratories/
methods  uncertain.  Despite  the  indication  of  increased
permeability in diabetes, edema has not been demonstrated in
the  retina  of  diabetic  mice  based  on  retinal  thickness
measurements (see section 2A3) [66,90]. Diabetic endothelial
nitric oxide synthase−/− mice exhibit accelerated and more
severe  retinal  vascular  permeability  than  age-matched
diabetic control mice [93].
2A5. Glial activation—Diabetes has not been found to
result in upregulation of GFAP in Muller glial cells in retinas
of C57Bl/6 mice [88,105] or Ins2Akita diabetic mice [85]. In
contrast, db/db diabetic mice were reported to show GFAP
induction in diabetes, and this glial activation was inhibited
in  animals  lacking  aldose  reductase  [87].  Activation  of
microglia (based on shape change) also occurs in the retinas
of diabetic mice [106], but is of unknown significance.
2B. Characteristic functional defects.
2B1.  Perfusion  and  autoregulation—Only  a  few
studies have been performed in diabetic mice [119-121], but
there  is  controversy  over  changes  in  steady-state  retinal
perfusion.  Nonetheless,  diabetic  mice  demonstrate  robust
alterations in retinal autoregulatory ability in response to a
provocation, similar to the defect reported in patients and
other experimental models [119-123] (Figure 2). Correction
of the retinal autoregulatory defect in diabetic mice is tightly
linked with normalization of biochemical abnormalities, and
is predictive of subsequent treatment efficacy [90,123,124].
2B2. Retinal function—The primary means of assessing
visual function in the mouse has been using electrophysiology
methods  such  as  ERG  [86,90,125,126].  These  ERG  data
provide evidence for dysfunction of both the outer retina and
inner retina in DR. However, because the ERG measures a
summed  response  from  the  entire  retina,  the  relationship
between  such  early  dysfunction  and  later  vascular
histopathology remains unclear.
Assessment  of  intraretinal  function  in  diabetes  using
MEMRI has also been reported, and genetic modifications
that inhibited development of the vascular lesions of DR have
been  found  to  normalize  the  MEMRI  response  [66],
suggesting a link between these events.
A  method  of  assessing  visual  processes  themselves
(contrast sensitivity and visual acuity) in mice has recently
become  available  [127-129]  via  measurement  of  the
optokinetic response. Using this method, diabetes-induced
reductions in contrast sensitivity and visual acuity have been
demonstrated  in  mice  (  [130],  Kern  et  al.  submitted,  and
Berkowitz et al. submitted).
3. ROBUST ENDPOINTS OF RETINOPATHY FOR
USE IN DIABETIC MICE
DR consists of a spectrum of retinal structural and functional
lesions. Since DR is a composite of several different lesions,
the presence of any one type of lesion is not sufficient to claim
that  it  is  present,  nor  is  the  correction  of  any  one  lesion
sufficient to claim that the retinopathy has been inhibited. The
fact that a particular species or strain does not develop the full
spectrum  of  those  lesions  of  retinopathy  is  obviously
unfortunate, but likely is due, at least in part, to important
differences between humans and rodents in the duration over
which they are exposed to diabetes. The lesions which do
develop in the animal models are characteristic of the early
stages of retinopathy, and are worthy of continued study to
identify promising new therapeutic targets at which to inhibit
progression of the retinopathy to more advanced and clinically
important stages (Table 1).
Characteristics  of  DR  in  patients  that  have  not  been
reproducibly replicated to date in diabetic mice are preretinal
neovascularization,  saccular  microaneurysms,  retinal
hemorrhage, and retinal thickening due to edema.
Nevertheless,  several  abnormalities  regarded  as
important in the development of DR (or at least characteristic
of it) in humans have been robustly identified in diabetic
mouse  models.  These  are  the  early  diabetes–induced
degeneration of retinal capillaries (Figure 1), loss of capillary
pericytes and neuroglia, impairment in vessel autoregulation
(Figure 2), and deterioration of nonvascular retinal function.
The  capillary  degeneration/nonperfusion  seems  to  be
especially  important,  because  it  is  found  in  patients  with
NPDR and is clinically linked to the eventual development of
PDR. A variety of validated techniques have been used to
assess  the  capillary  degeneration  and  the  results  of  using
different methods to isolate or view the retinal vessels (trypsin
digest  method,  elastase  method,  whole-mount
immunohistochemistry) have yielded similar conclusions. In
Molecular Vision 2010; 16:2121-2131 <http://www.molvis.org/molvis/v16/a227> © 2010 Molecular Vision
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2126contrast, a range of more or less validated (against standard
physiologic  methods)  techniques  have  been  use  to,  for
example, evaluate retinal blood flow, but with less agreement
between the methods. Thus, it is unclear if such disagreements
are methodological or biologic in nature. Better attempts to
validate and improve the physiologic accuracy of a chosen
technique should help in addressing this issue.
In addition to the “standard” techniques that have been
used to demonstrate changes in diabetic patients and rodents,
new techniques (including adaptive optics, OCT, oxygenation
mapping techniques, and MRI-based methods) are offering
exciting new and potentially noninvasive ways to assess these
(and other) DR lesions in the future.
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